Efficacy and safety of TCM combined with chemotherapy for SCLC: a systematic review and meta-analysis
Shuntai Chen,Yanju Bao,Jing Xu,Xiwen Zhang,Shulin He,Zhenhua Zhang,Runzhi Qi,Juling Jiang,Rui Liu,Qiujun Guo,Xing Zhang,Yupeng Xi,Honggang Zheng,Baojin Hua
DOI: https://doi.org/10.1007/s00432-020-03353-0
2020-01-01
Journal of Cancer Research and Clinical Oncology
Abstract:Background Chemotherapy is the standard treatment for small cell lung cancer (SCLC), but chemotherapy resistance and adverse reactions remain major problems. Although Traditional Chinese Medicine (TCM) is wildly applied for patients with SCLC in China, the evidence of TCM in the treatment for SCLC is limited. Purpose To evaluate the efficacy and safety of TCM combined with chemotherapy for patients with SCLC. Method We conducted a systematic search of PubMed, EMBASE, the Chinese National Knowledge Infrastructure, the VIP Information Database, and the Wanfang Database for randomized-controlled trials (RCTs) that are relevant. The included studies were reviewed by two investigators, with relevant data extracted independently. The effect estimate of interest was the relative risk (RR) or mean difference with 95% confidence intervals (95% CIs). Results 22 RCTs involving 1887 patients were included in this study. Compared with patients treated with chemotherapy© alone, those with Chinese herbal medicine and chemotherapy (TCM-C) had better therapeutic effects (RR = 1.295, 95% CI 1.205–1.391, P < 0.001), KPS scores (RR = 1.310, 95% CI 1.210–1.418, P < 0.001), 1-year survival rate (RR = 1.282, 95% CI 1.129–1.456, P < 0.001), 3-year survival rate (RR = 2.109, 95% CI 1.514–2.939, P < 0.001), and 5-year survival rate (RR = 2.373, 95% CI 1.227–4.587, P = 0.01). The incidence of gastrointestinal reaction (RR of = 0.786, 95% CI 0.709–0.870, P < 0.000) and bone marrow depression (RR = 0.837, 95% CI 0.726–0.965, P = 0.014) in TCM-C group were lower than that in the C group. Conclusion The systematic review indicated that TCM combined with chemotherapy may improve therapeutic effect, quality of life, and prolong survival time. More large-scale and higher quality RCTs are warranted to support our findings. PROSPERO registration number CRD42016038016.